

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.

Petitioner

v.

JANSSEN ONCOLOGY, INC.

Patent Owner

Case No. IPR2016-01332

U.S. Patent No. 8,822,438

**MOTION FOR *PRO HAC VICE* ADMISSION
OF BRYAN D. BEEL**

I. Statement of Precise Relief Requested

Mylan Pharmaceuticals Inc. (“Mylan”) hereby respectfully requests that the Patent Trial and Appeal Board (the “Board”) admit Bryan D. Beel, Ph.D., *pro hac vice* in this proceeding under 37 C.F.R. § 42.10(c).

Patent Owner has stated it will not oppose this motion.

II. Statement of Facts Showing Good Cause for the Board to Recognize Counsel *Pro Hac Vice* During the Proceeding

Under 37 C.F.R. § 42.10(c), the Board may admit counsel *pro hac vice* for good cause, so long as lead counsel is a registered practitioner and subject to any other conditions the Board requires. Under Section 42.10(c), good cause includes when “counsel is an experienced litigating attorney and has an established familiarity with the subject matter at issue in the proceeding.” This motion satisfies the requirements of Section 42.10(c):

1. Lead counsel, Brandon M. White, is a registered practitioner.
2. Dr. Beel is an experienced patent litigator and has an established familiarity with the subject matter at issue here, as shown in his accompanying January 23, 2017 Declaration (“Beel Decl.”), attached hereto. That declaration shows that Dr. Beel has been a litigator for nine years. He is a member in good standing of the Oregon State Bar, and is also admitted in the federal courts. Dr. Beel is also familiar with the subject matter of this case, including U.S. Patent No.

8,822,438 and its prosecution history, the underlying technology, and the prior art cited by the petitioner in this matter. Beel Decl. ¶¶ 8-9.

3. In his declaration, Dr. Beel also attests to each of the listed items required by the Order – Authorizing Motion for *Pro Hac Vice* Admission – 37 *C.F.R.* § 42.10 in IPR2013-00639. See Beel Decl. ¶¶ 2-13.

III. Conclusion

For the foregoing reasons, Mylan respectfully requests that the Board admit Bryan D. Beel, Ph.D., *pro hac vice* in this proceeding.

Dated: January 25, 2017

/Brandon M. White/

Brandon M. White

Reg. No. 52,354

PERKINS COIE LLP

700 13th Street, NW, Suite 600

Washington, D.C. 20005

Telephone: (202) 654-6204

Facsimile: (202) 654-6211

Email: bmwhite@perkinscoie.com

Attorney for Mylan Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing:

1. MOTION FOR *PRO HAC VICE* ADMISSION OF BRYAN D. BEEL, and
2. DECLARATION OF BRYAN D. BEEL IN SUPPORT OF MOTION FOR *PRO HAC VICE* ADMISSION OF BRYAN D. BEEL

was served electronically via email as follows:

Patent Owners:

Dianne B. Elderkin
Barbara L. Mullin
Ruben H. Munoz
Akin Gump Strauss Hauer & Feld LLP
JANS-ZYTIGA@akingump.com

David T. Pritikin
Bindu Donovan
Sidley Austin LLP
ZytigaIPRTeam@sidley.com

Dated: January 25, 2017

/Brandon M. White/
Brandon M. White

Attorney for Mylan Pharmaceuticals Inc.